Abstract:Ubiquitin-specific protease 22 (USP22) plays a prominent role in tumor development, invasion, metastasis and immune reprogramming, which has been proposed as a potential therapeutic target for cancer. Herein, we employed a structure-based discovery and biological evaluation and discovered that Rottlerin (IC<sub>50</sub> = 2.53 μM) and Morusin (IC<sub>50</sub> = 8.29 μM) and as selective and potent USP22 inhibitors. Treatment of HCT116 cells and A375 cells with each of the two compounds resulted in increased monoubiquitination of histones H2A and H2B, as well as reduced protein expression levels of Sirt1 and PD-L1, all of which are known as USP22 substrates. Additionally, our study demonstrated that the administration of Rottlerin or Morusin resulted in an increase H2Bub levels, while simultaneously reducing the expression of Sirt1 and PD-L1 in a manner dependent on USP22. Furthermore, Rottlerin and Morusin were found to enhance the degradation of PD-L1 and Sirt1, as well as increase the polyubiquitination of endogenous PD-L1 and Sirt1 in HCT116 cells. Moreover, in an in vivo syngeneic tumor model, Rottlerin and Morusin exhibited potent antitumor activity, which was accompanied by an enhanced infiltration of T cells into the tumor tissues. Using in-depth molecular dynamics (MD) and binding free energy calculation, conserved residue Leu475 and non-conserved residue Arg419 were proven to be crucial for the binding affinity and inhibitory function of USP22 inhibitors. In summary, our study established a highly efficient approach for USP22-specific inhibitor discovery, which lead to identification of two selective and potent USP22 inhibitors as potential drugs in anticancer therapy.

Development of a highly reliable assay for ubiquitin-specific protease 2 inhibitors.

Development of a robust HTRF assay with USP7 full length protein expressed in E. coli prokaryotic system for the identification of USP7 inhibitors

Development and Evaluation of a Highly Reliable Assay for SUMO-Specific Protease Inhibito R S

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

Validation of Catalytic Site Residues of Ubiquitin Specific Protease 2 (USP2) by Molecular Dynamic Simulation and Novel Kinetics Assay for Rational Drug Design

An Ultrasensitive System for Measuring the USPs and OTULIN Activity Using Nanoluc As a Reporter.

Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

In silico screening and computational evaluation of novel promising USP14 inhibitors targeting the palm-thumb pocket

Discovery of Novel USP8 Inhibitors Via Ubiquitin-Rho-110 Fluorometric Assay Based High Throughput Screening.

Structure-based Virtual Screening of Novel USP5 Inhibitors Targeting the Zinc Finger Ubiquitin-Binding Domain

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

Ubiquitin Specific Protease 2: Structure% Isoforms% Cellular Function% Related Diseases and Its Inhibitors

Chemical tools to define and manipulate interferon-inducible Ubl protease USP18

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Discovery of selective and potent USP22 inhibitors via structure-based virtual screening and bioassays exerting anti-tumor activity

USP7: Target Validation and Drug Discovery for Cancer Therapy

Cell-Based Covalent-Capture Deubiquitinase Assay for Inhibitor Discovery

Ubiquitin-specific Protease 20 in Human Disease: Emerging Role and Therapeutic Implications

Discovery of potent and selective activity-based probes (ABPs) for the deubiquitinating enzyme USP30

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy

USP13: Multiple Functions and Target Inhibition